CLINICAL TRIALS PROFILE FOR SANCTURA XR
✉ Email this page to a colleague
All Clinical Trials for SANCTURA XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00863551 ↗ | Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial | Completed | Allergan | Phase 4 | 2009-04-01 | This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory. |
| NCT00986401 ↗ | Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects | Completed | Allergan | Phase 1 | 2009-10-01 | The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered. |
| NCT01089751 ↗ | Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily | Completed | Allergan | Phase 4 | 2010-03-01 | This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy. |
| NCT01166438 ↗ | Anticholinergic vs. Botox Comparison Study | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 3 | 2010-03-01 | Urinary incontinence is a prevalent condition that markedly impacts quality of life and disproportionately affects women. Overactive Bladder syndrome (OAB) is defined as symptoms of urgency and frequency with urge urinary incontinence (OAB-wet) and without urge incontinence (OAB-dry). Conservative first line treatments for urge incontinence combined with other OAB symptoms (OAB-wet) include behavioral therapy, pelvic floor training +/- biofeedback, or the use of anticholinergic medications. These treatment modalities may not result in total continence and often drug therapy is discontinued because of lack of efficacy, side effects and cost or because of not wanting to take a pill. Behavioral therapy and pelvic muscle exercises require consistent, active intervention by the patient which is often not sustained. Thus, the objective of the Anticholinergic vs Botox Comparison Study (ABC) is to determine whether a single intra-detrusor injection of botulinum toxin A (Botox A®) is more effective than a standardized regimen of oral anticholinergics in reducing urge urinary incontinence. The null hypothesis is that there is no difference in the change from baseline in average number of urge urinary incontinence episodes over 6 months between groups. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SANCTURA XR
Condition Name
Clinical Trial Locations for SANCTURA XR
Trials by Country
Clinical Trial Progress for SANCTURA XR
Clinical Trial Phase
Clinical Trial Sponsors for SANCTURA XR
Sponsor Name
| Sponsor Name for SANCTURA XR | |
| Sponsor | Trials |
| Allergan | 4 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
